
Arndt Schottelius, Maxion Therapeutics CEO
Lilly-backed UK biotech raises $72M to advance its antibody approach
Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its pipeline of antibody-based candidates. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.